Add BrightSurf on Google Email

Formulary-related insurance denials of single-source branded drugs in the US

07.09.26 | JAMA Network
Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

About The Study: Among this large, diverse sample of individuals in the United States, formulary rejections were frequent and often resulted in delayed or absent treatment, highlighting trade-offs between cost and access to medicines.

Corresponding Author: To contact the corresponding author, Joseph F. Levy, PhD, email jlevy@jhu.edu .

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2026.8702)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.8702?guestAccessKey=b444c622-c50e-4c99-b93b-4c5c7541b7c6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070926

JAMA

Keywords

Article Information

Contact Information

JAMA Network Media Relations
JAMA Network
mediarelations@jamanetwork.org

How to Cite This Article

APA:
JAMA Network. (2026, July 9). Formulary-related insurance denials of single-source branded drugs in the US. Brightsurf News. https://www.brightsurf.com/news/8J4E537L/formulary-related-insurance-denials-of-single-source-branded-drugs-in-the-us.html
MLA:
"Formulary-related insurance denials of single-source branded drugs in the US." Brightsurf News, Jul. 9 2026, https://www.brightsurf.com/news/8J4E537L/formulary-related-insurance-denials-of-single-source-branded-drugs-in-the-us.html.